Go-Ichi-Ni-San 2: A potential biomarker and therapeutic target in human cancers

World J Gastrointest Oncol. 2022 Oct 15;14(10):1892-1902. doi: 10.4251/wjgo.v14.i10.1892.

Abstract

Cancer incidence and mortality are increasing globally, leading to its rising status as a leading cause of death. The Go-Ichi-Ni-San (GINS) complex plays a crucial role in DNA replication and the cell cycle. The GINS complex consists of four subunits encoded by the GINS1, GINS2, GINS3, and GINS4 genes. Recent findings have shown that GINS2 expression is upregulated in many diseases, particularly tumors. For example, increased GINS2 expression has been found in cervical cancer, gastric adenocarcinoma, glioma, non-small cell lung cancer, and pancreatic cancer. It correlates with the clinicopathological characteristics of the tumors. In addition, high GINS2 expression plays a pro-carcinogenic role in tumor development by promoting tumor cell proliferation and migration, inhibiting tumor cell apoptosis, and blocking the cell cycle. This review describes the upregulation of GINS2 expression in most human tumors and the pathway of GINS2 in tumor development. GINS2 may serve as a new marker for tumor diagnosis and a new biological target for therapy.

Keywords: Biomarker; Cancer; Clinicopathological characteristics; Go-Ichi-Ni-San; Go-Ichi-Ni-San 2; Molecular mechanism.

Publication types

  • Review